Sunday 00:00 amBarron's Bill Alpert thinks investors are overestimating the potential of Valeant Pharmaceuticals' (VRX) prospective epilepsy drug (retigabine) to offset waning royalties from its top-selling antiviral drug ribavirin. Two key issues are widespread complaints of side effects by test subjects, and a fierce push by prescription-drug plans to move patients to generics.
Comment!